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Abstract
Aims/hypothesis—Aldosterone concentrations increase in obesity and predict the onset of
diabetes. We investigated the effects of aldosterone on glucose homeostasis and insulin secretion
in vivo and in vitro.
Methods—We assessed insulin sensitivity and insulin secretion in aldosterone synthase-deficient
(As [also known as Cyp11b2]−/−)and wild-type mice using euglycaemic-hyperinsulinaemic and
hyperglycaemic clamps, respectively. We also conducted studies during high sodium intake to
normalise renin activity and potassium concentration in As−/− mice. We subsequently assessed the
effect of aldosterone on insulin secretion in vitro in the presence or absence of mineralocorticoid
receptor antagonists in isolated C57BL/6J islets and in the MIN6 beta cell line.
Results—Fasting glucose concentrations were reduced in As−/−mice compared with wild-type.
During hyperglycaemic clamps, insulin and C-peptide concentrations increased to a greater extent
in As−/− than in wild-type mice. This was not attributable to differences in potassium or
angiotensin II, as glucose-stimulated insulin secretion was enhanced in As−/− mice even during
high sodium intake. There was no difference in insulin sensitivity between As−/− and wild-type
mice in euglycaemic-hyperinsulinaemic clamp studies. In islet and MIN6 beta cell studies,
aldosterone inhibited glucose and isobutylmethylxanthine-stimulated insulin secretion, an effect
that was not blocked by mineralocorticoid receptor antagonism, but was prevented by the
superoxide dismutase mimetic tempol.
Conclusions/interpretation—We demonstrated that aldosterone deficiency or excess
modulates insulin secretion in vivo and in vitro via reactive oxygen species and in a manner that is
independent of mineralocorticoid receptors. These findings provide insight into the mechanism of
glucose intolerance in conditions of relative aldosterone excess.
Keywords
Aldosterone; Aldosterone synthase; Diabetes mellitus; Glucose clamp technique; Insulin;
Mineralocorticoid receptor; Pancreatic beta cells; Renin–angiotensin–aldosterone system
Introduction
Aldosterone classically stimulates sodium reabsorption in the distal nephron via the
mineralocorticoid receptor (MR), although many extra-renal effects are now appreciated.
Aldosterone contributes to myocardial fibrosis, nephrosclerosis and vascular injury even in
the absence of severe hypertension [1]. Although the renin-angiotensin-aldosterone system
(RAAS) is normally activated during conditions of low sodium or fluid intake, it may be
inappropriately elevated in obese individuals. In particular, elevated aldosterone
concentrations are associated with obesity and the metabolic syndrome [2–5]. This
correlation may be due to the stimulation of aldosterone synthesis by oxidised fatty acids or
other circulating aldosterone-stimulatory factors, which act on the adrenal gland
Luther et al. Page 2













independently of angiotensin II [6]. This relationship has led investigators to implicate
aldosterone in the development of diabetes, although a causal role has not been firmly
established [7].
Aldosterone excess produces insulin resistance in animals and correlates with insulin
resistance in humans [8, 9]. Insulin resistance progresses to overt type 2 diabetes when
pancreatic beta cells can no longer secrete sufficient insulin to maintain normoglycaemia
[10]. The effect of aldosterone on insulin secretion has not been extensively studied;
however, an inverse relation between insulin secretion and aldosterone tertiles was observed
in a cross-sectional study of hypertensive patients, suggesting an effect of aldosterone on
beta cell function [11]. Furthermore, blockade of the RAAS with either ACE inhibitors or
angiotensin receptor blockers (ARBs) has beneficial effects on glucose homeostasis, but the
mechanism remains uncertain [12, 13]. Because ACE inhibitors or ARBs decrease
aldosterone concentrations at least transiently, and the aldosterone and angiotensin pathways
are interrelated, the beneficial effects of these drugs may be mediated by alterations in
aldosterone signalling.
Aldosterone synthase is the primary enzyme responsible for production of aldosterone by
conversion of corticosterone to aldosterone. Aldosterone synthase-deficient mice (As [also
known as Cyp11b2]−/−) are incapable of producing aldosterone and provide a tool to
investigate the role of endogenous aldosterone in glucose metabolism [14, 15]. Using As−/−
mice and glucose clamp techniques, we investigated the role of endogenous aldosterone in
the regulation of insulin sensitivity and pancreatic beta cell function in mice. Because
potassium and renin activity are increased in As−/− mice during normal sodium intake [14],
we also performed studies during high sodium intake, which normalises these measures. We
also explored the direct effects of aldosterone and MR antagonism in isolated wild-type
murine islets and clonal beta cells.
Methods
Animals
All experiments were approved by the Vanderbilt Institutional Animal Care and Use
Committee. As−/− mice were generated on a 129 background [16] and were backcrossed
over ≥10 generations on to the C57BL/6J strain obtained from Jackson Laboratory (Bar
Harbor, ME, USA). Mice were genotyped as previously described [15]. We studied 12- to
16-week-old male mice. As−/− mice and their wild-type littermates had free access to
standard mouse chow (Rodent 5001; Purina Laboratory, Richmond, IN, USA) and water,
and were housed in a temperature-controlled facility with a 12 h light/dark cycle. During
high-sodium experiments, mice drank 0.9% saline (wt/vol.) for 1 week prior to study.
General clamp procedures
A surgically implanted gastric feeding tube and carotid arterial catheter were implanted for
glucose tolerance tests (GTTs). Carotid arterial and jugular venous catheters were implanted
for euglycaemic and hyperglycaemic clamps 3–5 days prior to study and clamp protocols
were conducted as previously described [17–19]. Basal samples were taken between t= −15
and 0 min in each clamp protocol after a 5 h fast, which started at 08:00 hours. During
hyperglycaemic clamps, a variable glucose infusion rate was used to increase and maintain
blood glucose at 13.9–16.7 mmol/l during the experimental period. Human insulin was used
during hyperinsulinaemic clamps (Humulin R; Eli Lilly, Indianapolis, IN, USA).
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Islet isolation, culture and perifusion
Murine islets were isolated from 12- to 18-week-old C57BL/6 J male mice and islet
perifusion performed as previously described [19]. Since steroids are present in FBS, which
is typically used in islet culture, we performed all cultures and assessments of insulin
secretion by isolated islets using steroid-free FBS (Sigma Aldrich, St Louis, MO, USA).
Purified islets were cultured for 16–24 h and at 37°C in RPMI-1640 with 5.6 mmol/l glucose
+ 10% steroid-free FBS, in the presence or absence of aldosterone, spironolactone,
eplerenone and tempol (all Sigma-Aldrich), and a combination of the treatments. After
overnight culture, insulin secretion was assessed using static incubation or a cell perifusion
system. Islets were matched for size and number, and assessed as islet equivalents (IEQ).
Static incubation studies were performed for 30 min at 37°C in fresh 2 ml RPMI-1640
containing 16.7 mmol/l glucose with or without treatment. Dynamic islet insulin secretion
was evaluated in a cell perifusion apparatus consisting of four parallel columns, with insulin
extracted as described previously [20].
Clonal beta cell culture and static insulin secretion studies
MIN6 cells originally obtained from J. Miyazaki [21] were cultured in DMEM containing
25 mmol/l glucose with 10% steroid-free FBS, 100 g/ml streptomycin, 100 units/ml
penicillin sulphate (Invitrogen, Carlsbad, CA, USA) and 70 µmol/l beta mercaptoethanol
(Sigma). Cells used in these studies were maintained at passage 24–30. Upon reaching 80%
confluence, cells were seeded into 24-well plates at 1×106 cells/well and maintained for 3–4
days. Fresh medium containing the indicated concentration of aldosterone, RU-28318
(Tocris Bioscience, Bristol, UK) or DMSO vehicle was added 12–16 h before studies.
During static incubation, cells were pre-incubated for 2 h with KRB without glucose, then
challenged for 1 h at 37°C with 500 µl KRB containing 0 or 23 mmol/l glucose. Treatment
or control drugs were present throughout static incubations. Insulin was measured using an
ELISA kit (ALPCO, Salem, NH, USA).
Laboratory assays
In all clamp protocols, arterial whole-blood glucose was measured using the glucose oxidase
method (Accu-Chek; Roche Diagnostics, Basel, Switzerland). Plasma collected during the
clamp studies or fractions from the perifusion studies were used for insulin and C-peptide
assays. Insulin and C-peptide concentrations were determined by RIA (Millipore, St.
Charles, MO, USA). In a separate group of animals during normal and high sodium intake
(10 wild-type, 12 As−/−), blood was collected via the saphenous vein into heparin-coated
tubes and immediately analysed for potassium (iSTAT EC8+ cartridge; Heska, Loveland,
TX, USA). Pancreatic insulin content and islet area were determined as previously described
[19].
Statistical analysis and calculations
Data are presented as mean±SEM unless otherwise specified. For comparisons between
genotype, Wilcoxon’s signed-rank test and Wilcoxon’s rank-sum test were used for paired
and unpaired comparisons respectively. Repeated-measures ANOVA was used with post
hoc least significant difference analysis to compare treatment effects between groups for
plasma measurements. Islet perifusion and static culture results were analysed using
ANOVA with study day as a covariate. All statistical analyses were performed using SPSS
for Windows (version 17.0; SPSS, Chicago, IL, USA), with a two-tailed value of p<0.05
considered to be significant.
Additional details
For other details on methods, see electronic supplementary material (ESM), Methods.
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Fasting blood glucose is reduced in As−/− mice without alteration of glucose tolerance
After a 5 h morning fast, arterial glucose was significantly lower in As−/− mice than in wild-
type controls (7.46±0.27 vs 8.75±0.33 mmol/l, p= 0.003) (Fig. 1a). Insulin tended to be
higher in As−/− mice (Fig. 1b). Because the circulating half-life of C-peptide is longer than
that of insulin, we also assessed C-peptide concentrations. C-peptide was significantly
increased in As−/− mice (Fig. 1c). Body weight, fat mass and gonadal fat weight were
similar in a separate set of age-matched wild-type and As−/− mice (see ESM, Results).
To assess whether fasting glucose, gastrointestinal glucose absorption and incretin signalling
were similar in As−/− and wild-type mice, we performed GTTs in wild-type (n=7) and As−/−
(n=7) mice via a previously implanted percutaneous gastric feeding catheter, with blood
sampling via arterial catheters. Whole-blood arterial glucose after a 5 h fast (08:00 to 13:00
hours) was higher in wild-type than in As−/− mice (9.21±0.44 vs 6.56±0.44 mmol/l,
respectively, p=0.004) (Fig. 1d), while fasting plasma insulin concentrations were 33.0±7.7
pmol/l in wild-type and 17.1±3.8 pmol/l in As−/−mice (p=0.09) (Fig. 1e). Glucose increased
significantly in both groups during the GTT, with peak values occurring at 10 min (Fig. 1d).
Although glucose remained higher in wild-type mice, the magnitude of change in glucose
was similar in wild-type and As−/− mice (16.6±1.39 vs 13.83±2.78 mmol/l, p=0.75). The
area under the glucose–time curve, corrected for baseline glucose, was also similar between
the two groups (p=0.32). Likewise, the absolute increase in insulin was similar in each group
(wild-type 66.7±26.1 vs 60.9± 14.5 pmol/l for As−/−, p=0.95) (Fig. 1e), despite higher
glucose concentrations in wild-type mice.
Glucose-stimulated insulin secretion is increased in As−/−mice independently of
potassium concentration and RAAS activation
To assess the effect of aldosterone deficiency on insulin secretion and to equalise
confounding differences in glucose concentrations between wild-type and As−/− mice, we
conducted hyperglycaemic clamps in nine wild-type and nine As−/− mice aged 12 to 18
weeks. Intravenous glucose was infused at variable rates as necessary to maintain plasma
glucose at similar steady-state levels (terminal 30 min of the study) in each genotype
(13.17±0.56 vs 14.11±0.44 mmol/l in wild-type vs As−/− mice, p=0.22) (Fig. 2a). Insulin
concentrations during steady-state glucose were significantly higher in As−/− mice than in
wild-type controls (47.9±4.64 vs 89.9±11.3 pmol/l wild-type vs As−/−, p=0.001) (Fig. 2b).
C-peptide concentrations were also significantly higher in As−/−mice, demonstrating that
increased insulin concentrations in As−/− mice resulted from insulin secretion, rather than
altered insulin metabolism (p<0.01)(Fig. 2c). The terminal glucose infusion rate was similar
in the two groups (1.45±0.43 vs 1.50±0.37 mmol kg−1 min−1, p=0.67).
In mice ingesting a normal sodium diet, serum potassium was significantly higher in As−/−
mice (5.0±0.2 vs 5.8± 0.2 mmol/l, wild-type vs As−/−, p=0.004).Because potassium
stimulates insulin secretion, and high sodium intake normalises serum potassium and renin
activity in As−/−mice [16], we repeated hyperglycaemic clamps in mice during high sodium
intake (five wild-type, four As−/−). During high sodium intake (0.9% saline drinking for 5–7
days), potassium in As−/− mice was similar to that of wild-type, (5.2±0.2 vs 5.3±0.2 mmol/l,
wild-type vs As−/−, p= 0.88). Glucose concentration was similar at steady state (13.83±0.56
vs 13.33±0.56 mmol/l, wild-type vs As−/−, p=0.73) (Fig. 2d), while insulin (47.0±6.4 vs
127.6±9.3 pmol/l, wild-type vs As−/−, p=0.016) (Fig. 2e) and C-peptide (514±50 vs 966±121
pmol/l, wild-type vs As−/−, p=0.001) (Fig. 2f) were again significantly higher in As−/−mice.
The terminal glucose infusion rate required to maintain equivalent serum glucose
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concentrations was significantly higher in the As−/− than in the wild-type group (3.26±0.076
vs 1.17±0.073 mmol kg−1 min−1,p=0.016), reflecting the increased insulin concentration.
Pancreatic islet density and insulin content are unaltered in As−/− mice
To determine whether increased glucose-mediated insulin secretion resulted from increased
beta cell mass, we assessed pancreatic insulin content and conducted quantitative
morphometric analysis of pancreatic tissue from As−/− and wild-type mice. Pancreatic
insulin content was similar in both groups (132.7±11.7 and 149.8± 13.9 nmol/g tissue, wild-
type [n=5] and As−/− [n=4], p= 0.56). Likewise, pancreatic islet area was similar between
the two groups (0.46±0.08 vs 0.50±0.10% of total pancreas area, n=5 each group, p=0.92).
Aldosterone impairs insulin secretion in isolated murine islets and MIN6 beta cells
To further exclude confounding by systemic effects of aldosterone and to better assess the
direct effect of aldosterone on pancreatic islet cell function, we conducted studies in isolated
wild-type murine islets. In a dose-ranging study, islets were cultured for 24 h in the presence
of aldosterone and then stimulated with 16.7 mmol/l glucose in static culture for 30 min on
the following day (n≥5 replicates each group). Aldosterone impaired glucose-stimulated
insulin response in a dose-dependent manner (Fig. 3a). Islet insulin content, assessed after
study completion, did not differ between treatment groups (p=0.37) (Fig. 3a). Because the
results were not affected by normalisation for islet insulin content, these studies suggest that
aldosterone affects glucose sensing or stimulus–response coupling, rather than insulin
production. Similar results were obtained in the MIN6 beta cell line during static culture,
with maximal inhibition achieved between 10 and 100 nmol/l concentration (Fig. 3b). Under
unstimulated conditions (0 mmol/l glucose in MIN6), 100 nmol/l aldoste-rone slightly
decreased insulin secretion (p=0.03).
We performed perifusion studies of isolated islets using aldosterone at concentrations of 10
and 1,000 nmol/l after overnight culture (Fig. 3c, d). Aldosterone decreased glucose- and
isobutylmethylxanthine (IBMX)-stimulated insulin secretion in a dose-dependent manner
(Fig. 3d, e), with a significant effect of 10 nmol/l aldosterone evident during peak IBMX
stimulation (ESM Fig. 1) and a trend towards significance during peak glucose stimulation
(p= 0.06). Aldosterone also impaired tolbutamide-induced insulin secretion (10.5±0.9 vs
15.8±1.7 pmol min−1 IEQ−1 in the presence and absence of aldosterone, respectively,
p<0.01). Aldosterone did not affect insulin secretion during the baseline period (5.5 mmol/l
glucose).
Aldosterone impairs insulin secretion in an MR-independent manner
We tested the effect of the specific MR antagonist eplerenone at 10 µmol/l, a concentration
greater than the established IC50 of 360 nmol/l [22, 23], on insulin secretion in perifused
islets. Aldosterone significantly decreased insulin secretion in response to glucose and
IBMX. Eplerenone alone did not affect insulin secretion or insulin content, or prevent the
effect of aldosterone in perifused islets. Results were similar in response to glucose and
IBMX (ESM Fig. 2a, b). We also tested a higher molar ratio of eplerenone to aldosterone by
lowering the aldosterone concentration in isolated islet static culture: results were similar,
suggesting that inadequate competition alone could not explain these results (Fig. 4a).
Results were similar during spironolactone treatment (ESM Fig. 2c, d). In MIN6 cells, the
water-soluble MR antagonist RU-28318 (10 µmol/l) alone reduced insulin secretion and did
not prevent the effect of aldosterone (Fig. 4b). Furthermore, MR protein abundance was
markedly lower in MIN6 cells than in renal cortex (Fig. 4c). Glucocorticoid receptor
antagonism with mifepristone (10 µmol/l) did not prevent the effect of aldosterone within
isolated islets. However, pretreatment with the superoxide dismutase mimetic, tempol,
prevented the effect of aldosterone on insulin secretion (Fig. 4d). These studies suggest that
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aldosterone alters insulin secretion in pancreatic islets and clonal beta cells via a mechanism
that is independent of MR and glucocorticoid receptor, and involves generation of reactive
oxygen species.
Mr mRNA is expressed in murine pancreatic islets
To determine whether the MR is expressed in pancreatic islets, we assessed relative mRNA
concentrations in pancreatic islets (n=4) and MIN6 cells (n=3), compared with renal cortex
(n=4) from wild-type mice (Table 1). Mr (also known as Nr3c2) gene expression in isolated
murine islets was similar to that in the renal cortex, with a trend towards being reduced in
MIN6 cells. When compared within pancreatic islets, Mr mRNA was expressed at a much
lower level than the beta cell-specific transcription factor Mafa (Table 2). Because 11beta-
hydroxysteroid dehydrogenase types I and II affect the ability of glucocorticoids to activate
the MR, we also assessed 11 βHsd1 and 11βHsd2 (also known as Hsd11b1 and Hsd11b2,
respectively) mRNA concentration. mRNA of 11βHsd1 and 11βHsd2 was detectable at
much lower levels in the pancreatic islets and MIN6 cell line than with the respective
concentrations in kidney (fold change p≤0.02 for each) (Table 1).
We performed immunohistochemistry on pancreatic islet sections to localise the MR, using
a monoclonal antibody targeting the MR N-terminal amino acids 1–18 [24]. The MR co-
localised with somatostatin- and pancreatic polypeptide-containing cells at the periphery of
the islets (Fig. 5). However, the MR did not co-localise with insulin or glucagon. Because
the pancreatic islet is a highly vascularised structure, we also stained for the blood vessel
endothelial marker CD31, but found no co-localisation (ESM Fig. 3).
Insulin sensitivity is unchanged in As−/− mice
To determine whether endogenous aldosterone affects insulin sensitivity, we performed
euglycaemic–hyperinsulinaemic clamps in three wild-type and six As−/− mice. Insulin (4
mU kg−1 min−1) and glucose (variable rate) were infused intravenously to normalise glucose
concentrations and the glucose infusion rate at the terminal portion of the study was used as
an estimate of insulin sensitivity. Glucose concentrations during steady state (i.e. the
terminal 30 min of the study) were maintained at 7.33± 0.58 mmol/l in wild-type and
6.64±0.35 mmol/l in As−/− mice (p=0.26) (Fig. 6a). The average terminal glucose infusion
rate was similar in both groups (0.240±0.016 vs 0.222± 0.021 mmol kg−1 min−1, wild-type
vs As−/−, p=0.71) (Fig. 6c). Insulin concentrations were also statistically similar at steady
state (67.47±8.4 vs 80.9±12.3 pmol/l, wild-type vs As−/−, respectively, p=0.79). Tissue-
specific glucose uptake, determined from the accumulation of 2-deoxy-[14C]glucose
phosphate in tissue (brain, adipose and muscle) from 2-deoxy-[14C]glucose injected
intravenously during the clamp, was similar in the two genotype groups, with the exception
of adipose tissue (Table 3), indicating that overall insulin action was similar in both mouse
groups. Euglycaemic–hyperinsulinaemic clamps were also performed during high sodium
intake in order to suppress endogenous aldosterone in wild-type mice and to control for
alterations of potassium and angiotensin in As−/− mice. Insulin sensitivity was unchanged by
sodium intake and was similar among groups. No differences in tissue-specific glucose
uptake or endogenous glucose production were observed (Fig. 6b, d, Table 3).
Discussion
The present study demonstrates that aldosterone deficiency enhances glucose-stimulated
insulin secretion in vivo and that this effect is independent of electrolyte disturbance, insulin
sensitivity or renin activity in As−/−mice. Excess aldosterone, at a concentration consistent
with that seen in primary aldosteronism and the metabolic syndrome, reduced insulin
secretion in isolated perifused murine islets and in clonal beta cells through a mechanism
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that is independent of MR. To our knowledge, this is the first study to demonstrate that
endogenous aldosterone regulates insulin secretion and that perturbation of aldosterone
directly alters insulin secretion within beta cells.
Mouse and rat models harbouring renin transgenes exhibit altered glucose homeostasis [25,
26]. Supra-physiological concentrations of angiotensin II and aldo-sterone impair insulin
sensitivity in skeletal muscle of rodents [27, 28]. Recent studies demonstrating the presence
of RAAS components in pancreatic islets suggest that renin or angiotensin II also play a
physiological role in insulin secretion [29, 30]. Clinical studies in humans suggest that
interruption of the RAAS may reduce diabetes risk [31]. The ARB valsartan prevented
progression to diabetes in participants with impaired glucose tolerance [13]. In the Diabetes
Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial, the
ACE inhibitor ramipril improved the incidence of normoglycaemia, but not the development
of diabetes [12]. Because previous observational studies of the effect of RAAS blockade on
diabetes risk have been performed in patients with congestive heart failure and during
diuretic use, lack of diuretic-induced RAAS activation in the DREAM trial may have
diminished the effect of ramipril [31].
Most human studies on the effect of hyperaldosteronism have focused on insulin sensitivity,
while none has assessed insulin secretion using hyperglycaemic clamps. Sindelka et al.
demonstrated that surgical removal, but not spironolactone treatment, improved insulin
sensitivity in patients with aldosterone-producing adenomas [32]. Other studies have yielded
mixed findings in patients with primary aldosteronism [32, 33]. Furthermore, studies that
have estimated insulin sensitivity by HOMA may be confounded by differences in insulin
secretion [34].
To date, few studies have addressed the effects of aldosterone on insulin secretion in
pancreatic islets. Pierluissi et al. mentioned that aldosterone (8 nmol/l) reduced insulin
secretion by 18% in isolated rat islets compared with controls, but did not assess the effect
of aldosterone on the beta cell, the dose–response or the effect of MR antagonism [35]. Our
studies expand substantially on these preliminary findings, providing direct evidence that
aldosterone affects insulin secretion in vivo and in vitro, and demonstrating that this effect is
independent of MR and the glucocorticoid receptor, and is mediated via production of
reactive oxygen species. Moreover, studies in the MIN6 cell line suggest that aldosterone
exerts this effect directly within beta cells.
In vivo, aldosterone synthase deficiency could affect insulin secretion due to indirect effects
of increased angiotensin II or potassium. During normal sodium intake, relative volume
depletion and increased angiotensin II in As−/− mice would be expected to decrease islet
blood flow and insulin secretion. However, potassium is also elevated under these
conditions in As−/− mice and directly stimulates insulin secretion in isolated islets. We
controlled for these possible confounders in two ways. First, we studied As−/− mice treated
with a high sodium diet, which reduces plasma renin activity, angiotensin II and plasma
potassium [14]. In this setting, we found that glucose-stimulated insulin secretion was
enhanced further in As−/− mice, even though potassium and plasma renin activity were
comparable in wild-type and As−/−mice under these conditions. Second, aldosterone reduced
insulin secretion in isolated perifused islets and MIN6 cells, during which potassium
concentration and perfusion pressure were held constant. Although circulating
glucocorticoids could affect insulin secretion in As−/− mice, we have previously determined
that corticosterone is unchanged compared with wild-type littermates [15]. In addition, we
used steroid-free culture media during the in vitro studies specifically to avoid the
confounding effect of glucocorticoids.
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To assess the contribution of the MR to effects of aldosterone on insulin secretion, we
examined the abundance and localisation of the MR within pancreatic islets. Chuang et al.
have characterised the nuclear hormone receptor mRNA profile in islets and demonstrated
expression of MR mRNA within isolated murine and human islets [36]. We also found that
Mr mRNA is expressed in pancreatic islets, and localised to a subset of cells in the islet
periphery (delta and pancreatic polypeptide cells), rather than to beta cells. The effect of
aldosterone on insulin secretion in cultured MIN6 cells demonstrates that aldosterone exerts
a direct effect on beta cells, while the low abundance of MR protein in beta cells also
suggests an MR-independent mechanism. Our pharmacological studies also confirm that
aldosterone regulates insulin secretion via an MR-independent mechanism.
Specifically, the MR antagonists spironolactone, eplerenone and RU-28318 did not prevent
inhibition of insulin secretion by aldosterone, suggesting that aldosterone affects insulin
secretion via an MR-independent mechanism. The classic aldosterone signalling pathway
within the principal cells of the kidney involves MR activation, homo-dimerisation,
translocation to the nucleus and increased transcription of target genes. However,
aldosterone may also exert non-genomic and MR-independent effects in non-epithelial
tissues such as the vasculature, cardiomyocytes and other tissues [37]. The non-genomic
effects of aldosterone do not involve DNA transcription, and in some cases are not blocked
by MR antagonists [37–41]. The finding that aldosterone attenuated insulin secretion in
response to glucose, IBMX and the sulfonylurea tolbutamide suggests that aldosterone
exerted an effect downstream from KATP. Moreover, our data suggest that aldosterone
impairs insulin secretion by increasing the production of reactive oxygen species.
Aldosterone is known to induce oxidative stress in other settings [42], and reactive oxygen
species impair insulin secretion [43].
The finding that aldosterone impairs insulin secretion in vitro and in vivo may have broad
implications for patients with insulin resistance and impaired glucose tolerance, because
impaired beta cell function is a necessary step in progression to type 2 diabetes [10]. Since
plasma aldosterone concentrations are inappropriately elevated in obesity [2], aldosterone
may be a critical link between obesity and the insulin resistance and impaired insulin
secretion that produce overt diabetes. Although previous studies have demonstrated that
aldosterone and the MR promote adipocyte differentiation in vitro [44], As−/− mice
exhibited no difference in adiposity measures, suggesting that aldosterone deficiency alone
may not reduce adipose mass. Rather, it appears that fatderived factors promote aldosterone
secretion in the setting of obesity and the metabolic syndrome [6]. We therefore hypothesise
that aldosterone could further contribute to diabetes progression by impairing the insulin
secretory response. Interestingly, insulin secretion was impaired in a cross-sectional study of
patients with aldosterone-producing adenomas, although this correlated with altered serum
potassium [45]. More recently, Mosso et al. applied HOMA-2 to a group of patients with
primary aldosteronism and found evidence of impaired beta cell function compared with
patients with essential hypertension that was independent of serum potassium [11].
Our data may have particular relevance to the use of MR antagonists in diabetic participants
and to the ongoing development of aldosterone synthase inhibitors. Treatment with either
spironolactone or eplerenone increases plasma aldosterone concentrations, regardless of
whether an ACE inhibitor or ARB is co-administered [46]. Glycaemic control worsened
during spironolactone treatment in a randomised, placebo-controlled study in diabetic
participants [47]. An additional observational study detected an increased incidence of
diabetes in spironolactone-treated patients compared with losartan-treated patients [48]. The
observation that aldosterone decreases insulin secretion through an MR-independent
mechanism may explain these findings [47, 49], and further studies investigating this effect
are warranted. During long-term ACE inhibitor or ARB administration, aldosterone
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increases back to baseline values, despite an initial suppression. Pharmacological agents that
specifically target aldosterone synthase reduce plasma aldosterone in humans and could
provide a therapeutic alternative in the future [50].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ARB Angiotensin receptor blocker
DREAM Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication
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Fasting glucose is lower and oral glucose tolerance is normal in As−/− mice. a Data from
pooled studies demonstrate that fasting plasma glucose was significantly lower in As−/− than
in wild-type (WT) mice (n≥25 per each genotype). Fasting insulin (b) tended to increase
(p=0.07, n≥25) and C-peptide (c) was significantly higher in As−/− mice (n≥17). d During
the GTTs, glucose was reduced in As−/− (triangles) compared with wild-type (circles) mice,
although the changes in glucose and baseline-corrected AUC glucose results were similar. e
The baseline-corrected AUC insulin was also similar. *p≤ 0.05, **p≤0.01 between
genotypes
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Glucose-stimulated insulin secretion is increased in As−/− mice. During hyperglycaemic
clamp studies under normal sodium (a–c) and high sodium (d–f) conditions, glucose was
infused to achieve equivalent glucose values at the terminal phase of the study. Terminal
glucose (a, d) was similar in As−/− (triangles) compared with wild-type (circles) mice.
Insulin (b, e) and C-peptide (c, f) concentrations were significantly greater in As−/− than in
wild-type mice. *p≤0.05, **p≤0.01 and ***p≤0.001 vs wild-type
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Aldosterone decreases insulin secretion in a dose-dependent manner in isolated islets and the
MIN6 beta cell line. a Aldosterone reduced glucose-stimulated insulin concentrations,
assessed as insulin secreted after 16.7 mmol/l glucose stimulus for 30 min in static culture
(grey bars). Total islet insulin content was unaltered by aldosterone (white bars), suggesting
an effect on insulin secretion rather than insulin content. b In MIN6 cells, aldosterone
decreased insulin secretion in response to 23 mmol/l glucose (grey bars), reaching maximal
inhibition at 100 nmol/l. c In isolated islet perifusion studies, insulin secretion in response to
glucose (16.7 mmol/l) and isobutyl-methylxanthine (IBMX; 100 µmol/l) was diminished in
the presence of aldosterone 1000 nmol/l (triangles) compared with control (circles). d
Insulin secretion quantified as insulin AUC was significantly lower in islets treated with
aldosterone (1000 nmol/l) in response to glucose (16.7 mmol/l) and (e) to glucose (16.7
mmol/l)+IBMX (100 µmol/l). *p≤0.05 and ***p≤0.001 vs 0 nmol/l aldosterone
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Aldosterone impairs insulin secretion via an MR-independent mechanism and oxidative
stress. a Eplerenone (EPL) did not prevent the effect of aldosterone (Aldo) on insulin
secretion in isolated islet static culture. b The water-soluble MR antagonist RU-28318 did
not prevent the effect of aldosterone in the clonal MIN6 cell line (0 mmol/l glucose, white
bars; 23 mmol/l glucose, grey bars). c MR protein abundance was markedly reduced in
MIN6 cells compared with renal cortex. d The antioxidant tempol prevented the effect of
aldosterone in isolated islet studies. *p<0.05 and **p≤0.01 vs control
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The MR is produced in pancreatic delta and pancreatic polypeptide-positive cells in isolated
murine islets. Immunofluorescence staining was performed on three consecutive sections of
isolated murine islets embedded in collagen (40× objective). The MR (green) localised to
the islet periphery and did not co-localise with insulin (blue pseudocolour) or glucagon (red,
top row). The MR also co-localised with somatostatin- (SS, red, middle row) and pancreatic
polypeptide-positive (PP) cells (red, bottom row). Scale bar 100 µm
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Insulin sensitivity is similar in wild-type and As−/−mice. Blood glucose (a, b) and glucose
infusion rate (c, d) during euglycaemic-hyperinsulinaemic clamp studies in wild-type
(circles) and As−/− (triangles) mice while under normal (a, c) and high sodium intake (b, d).
*p≤0.05 vs wild-type
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Table 1
Relative mRNA expression
Tissue Mr 11βHsd1 11βHsd2
Renal cortex 1.01±0.09 1.00±0.06 1.03±0.10
Pancreatic islets 1.12±0.19 0.02±0.007*** 0.002±0.0006***
MIN6 cell line 0.68±0.08† 0.0033±0.001** 0.0067±0.001***




p<0.001 vs renal cortex
†
p=0.07 vs pancreatic islets
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Table 2
Relative mRNA expression in pancreatic islets
Variable Mafa Mr 11βHsd1 11βHsd2
Relative expression 1.03±0.15 0.15±0.02*** 0.06±0.02*** 0.01±0.002***
Data are expressed as mean±SEM fold-changes vs Mafa for each gene of interest; 18S was used as endogenous control
***
p<0.001 vs Mafa
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Table 3
Endogenous glucose production and tissue-specific glucose uptake during eugly-caemic–hyperinsulinaemic
clamp during normal and high sodium intake









EndoRa (mg kg−1 min−1) NA NA 15.4±2.0 15.1 ±0.9
Tissue Rg (µg min−1[mg tissue]−1)
Gastrocnemius 14.6±2.1 9.4±2.2 16.5±4.8 12.8±2.2
Vastus lateralis 14.0±2.3 8.7±2.1 14.3±2.2 10.9±1.9
Soleus 79.8±19.7 54.4±15.2 85.3±24.2 46.0±8.4
Diaphragm 133.7±43.8 152.9±15.0 107.3±20.0 80.9±15.3
Heart 394.1±45.3 349.5±40.2 239.3±68.7 206.2±29.9
Adipose 3.35±1.0 9.06±1.9* 6.3±1.8 5.9±1.0
Brain 60.6±8.7 49.1±3.0 53.7±11.9 38.6±4.8
Data are expressed as mean± SEM
EndoR was not assessed during normal sodium
EndoRa, endogenous glucose production;Rg, glucose uptake
*
p<0.05 vs wild-type
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